Dizal Pharma is a biopharmaceutical company dedicated to the discovery, development, and commercialization of differentiated therapeutics for cancer and hematological diseases. Founded in 2017, the company builds on translational science and molecular design to develop medicines addressing disease mechanisms and patient populations where significant unmet medical needs remain.

Dizal has built a portfolio spanning approved medicines and late-stage investigational therapies, with programs being developed across solid tumors and hematological malignancies. Its leading products include ZEGFROVY, an oral EGFR inhibitor approved in both the United States and China for certain patients with non-small cell lung cancer, and golidocitinib, approved in China for relapsed or refractory peripheral T-cell lymphoma. The company is also advancing additional therapies targeting lung cancer and B-cell malignancies through global clinical development.